• Explore /
  • Poster
  • / Preliminary safety analysis of phase II open-label NIVACOR trial (GOIRC-03-2018) in patients with advanced colorectal cancer RAS or BRAF mutated.

Preliminary safety analysis of phase II open-label NIVACOR trial (GOIRC-03-2018) in patients with advanced colorectal cancer RAS or BRAF mutated.

Abstract Poster

Authors

null

Angela Damato

Medical Oncology Unit, Clinical Cancer Center, AUSL-IRCCS Reggio Emilia, Reggio Emilia, Italy

Angela Damato , Annalisa Berselli , Francesco Iachetta , Alessandra Romagnani , Mario Larocca , Alicia Garcia Arias , Lorenzo Antonuzzo , Guglielmo Nasti , Francesca Bergamo , Carmine Pinto

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session: Colorectal Cancer

Track

Colorectal Cancer

Sub Track

Patient-Reported Outcomes and Real-World Evidence

Clinical Trial Registration Number

NCT04072198

Citation

J Clin Oncol 39, 2021 (suppl 3; abstr 37)

DOI

10.1200/JCO.2021.39.3_suppl.37

Abstract #

37

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Angela Damato

First Author: Dale Randall Shepard

First Author: Sheng Li

First Author: Zev A. Wainberg